Current
Gene Therapy is a popular, bi-monthly peer-reviewed
journal from Bentham Science Publishers. It is an impact factor journal (5.318)
indexed in major abstracting agencies, such as Scopus,
EMBASE, MEDLINE/Index Medicus, and Journal Citation Reports etc. Current Gene
Therapy publishes major topics concerning basic and clinical applications of
gene and cell therapy.
The advances in the studies of
Hematology (the study of blood) have shown that many diseases can be cured by
making changes in the genetic coding. One of the disease is Hematological
malignancy. It is the term given to a class of cancers that attack and affect
the blood, bone marrow and lymph nodes. Often, the patients suffering from
Leukemia, Lymphomas and Myelomas do not find a lasting cure for their ailment
and do not survive the illness.
New developments in the research are
showing promising results. They have indicated that that gene therapy can
actually prove to bring unprecedented progress to the treatment of blood
cancers. For instance, researchers are much more optimistic that using gene
therapy, the blood cells can actually be used as attack cells against the
cancer. The experiments so far have given promising results, and patients show
no signs of cancer after the treatment. This is true even for serious patients
who were suffering from acute lymphocytic leukemia, myeloma, and chronic
lymphocytic leukemia and were taking chemotherapies for years.
The doctors separate the white blood
cells from the blood stream of the patient, in bulk quantities. The blood
sample is then taken to a laboratory to infuse the special gene, which targets
cancer, in the blood. When the process is complete, the blood carrying the
special gene is transferred into the patient’s circulation. This procedure
ensures that the treatment of cancer is successful, a less risky and more
productive method than chemos, stem cell or bone marrow transplants.
[This news is based
on the article by Marilynn Marchione, ‘Gene
Therapy Scores Big Wins against Blood Cancers’]
No comments:
Post a Comment